MEDIPOST has been invited to consecutive international stem cell academic forums held in Singapore and Taiwan.

MEDIPOST is participating in a symposium held by ‘Stem Cell Society Singapore’ on 17~18th, followed by ‘International forum on regulation of cell therapy’ held by Taiwanese FDA on 19~20th.

The symposium in Singapore was held with the topic of ‘Future forecasts of stem cell treatment industry’. Major universities and governmental bodies in Asia, US and Europe along with major stem cell related companies such as Mesoblast (Australia) and GE Healthcare (US) participated in the meeting.

The forum in Taiwan invited KFDA, FDA (US) and health ministry advocates of Japan, Singapore and Taiwan, along with global pharmaceuticals such as Novartis and Merck. The regulations and policies regarding clinical trials and approval of cell treatments in each country were shared in the forum.

MEDIPOST was the only Korean company invited, in both of the meetings.

MEDIPOST presented on the approval process, local marketing status and long-term follow up clinical study results of ‘CARTISTEM^®’, a knee cartilage loss treatment for degenerative osteoarthritis patients, and also presented on the market potential and competitiveness of stem cell treatments.